Metabolic codependencies in the tumor microenvironment and gastric cancer: Difficulties and opportunities.


Journal

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 29 01 2023
revised: 21 03 2023
accepted: 23 03 2023
medline: 3 5 2023
pubmed: 30 3 2023
entrez: 29 3 2023
Statut: ppublish

Résumé

Oncogenesis and the development of tumors affect metabolism throughout the body. Metabolic reprogramming (also known as metabolic remodeling) is a feature of malignant tumors that is driven by oncogenic changes in the cancer cells themselves as well as by cytokines in the tumor microenvironment. These include endothelial cells, matrix fibroblasts, immune cells, and malignant tumor cells. The heterogeneity of mutant clones is affected by the actions of other cells in the tumor and by metabolites and cytokines in the microenvironment. Metabolism can also influence immune cell phenotype and function. Metabolic reprogramming of cancer cells is the result of a convergence of both internal and external signals. The basal metabolic state is maintained by internal signaling, while external signaling fine-tunes the metabolic process based on metabolite availability and cellular needs. This paper reviews the metabolic characteristics of gastric cancer, focusing on the intrinsic and extrinsic mechanisms that drive cancer metabolism in the tumor microenvironment, and interactions between tumor cell metabolic changes and microenvironment metabolic changes. This information will be helpful for the individualized metabolic treatment of gastric cancers.

Identifiants

pubmed: 36989719
pii: S0753-3322(23)00389-X
doi: 10.1016/j.biopha.2023.114601
pii:
doi:

Substances chimiques

Cytokines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

114601

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare that there is no conflicts of interests.

Auteurs

Xihe Zhao (X)

Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.

Kai Li (K)

Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.

Mengyu Chen (M)

Department of Clinical Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China.

Lei Liu (L)

Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, People's Republic of China. Electronic address: liuleicmu2h@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH